Moving cancer care closer to home: a single-centre experience of home chemotherapy administration for patients with myelodysplastic syndrome

Por Murthy, Vidhya, Wilson, Jacqueline, Suhr, Julie, James, Lydia, Tombs, Harley, Shereef, Elmoamly, Nikolousis, Emmanuel
Publicado no ESMO Open (2019)

HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer

Por Nakamura, Yoshiaki, Sawada, Kentaro, Fujii, Satoshi, Yoshino, Takayuki
Publicado no ESMO Open (2019)

Correction: Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish...

Publicado no ESMO Open (2020)

Correction: European society for medical oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows

Publicado no ESMO Open (2020)

Correction: Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Va...

Publicado no ESMO Open (2020)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma

Por Eberst, Lauriane, Cassier, Philippe A, Brahmi, Mehdi, Tirode, Franck, Blay, Jean-Yves
Publicado no ESMO Open (2020)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies

Por Ardini, Elena, Siena, Salvatore
Publicado no ESMO Open (2020)

Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy

Por Wagner, Anna Dorothea
Publicado no ESMO Open (2020)

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?

Por Ricci, Angela Dalia, Rizzo, Alessandro, Brandi, Giovanni
Publicado no ESMO Open (2020)

FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?

Por Lamarca, Angela, Foster, Lucy, Valle, Juan W, Satyadas, Thomas, Siriwardena, Ajith
Publicado no ESMO Open (2020)

Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer

Por Smyth, Elizabeth C, Cervantes, Andrés
Publicado no ESMO Open (2020)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

Por Franzoi, Maria Alice, de Azambuja, Evandro
Publicado no ESMO Open (2020)

Correction: Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project)

Publicado no ESMO Open (2020)

Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer

Por Gaschler-Markefski, Birgit, Sikken, Patricia, Heymach, John V, Gottfried, Maya, Mellemgaard, Anders, Novello, Silvia, Gann, Claudia-Nanette, Barrueco, José, Reck, Martin, Hanna, Nasser H, Kaiser, Rolf
Publicado no ESMO Open (2017)

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer

Por Kitano, Atsuko, Ono, Makiko, Yoshida, Masayuki, Noguchi, Emi, Shimomura, Akihiko, Shimoi, Tatsunori, Kodaira, Makoto, Yunokawa, Mayu, Yonemori, Kan, Shimizu, Chikako, Kinoshita, Takayuki, Fujiwara, Yasuhiro, Tsuda, Hitoshi, Tamura, Kenji
Publicado no ESMO Open (2017)

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Por Wu, Yi-Long, Wang, Chang-Li, Sun, Yan, Liao, Mei-Lin, Guan, Zhong-Zhen, Yang, Zhi-Min, Zhou, Qing-Hua, Lu, Shun, Cheng, Ying, Liu, Xiao-Qing, Zhang, Xu-Chao, Zhou, Caicun, Wang, Jie, Zhou, Qing, Song, Yong, Han, Bao-Hui, Ma, Zhi-Yong, Yang, Fan, Wang, Qun, Chuai, Shao-Kun, Shao, Yang, He, Wei, Zhu, Guanshan, Xiong, Lei, Wang, Jian-Jun, Chen, Ke-Neng, Zhang, Li, Mao, Wei-Min, Ma, Sheng-Lin, Feng, Ji-Feng, Yang, Xue-Ning, Xu, Lin, Chen, Gang, Zhao, Jian, Song, Qi-Bin, SHEN-TU, Yang, Qiao, Gui-Bin, Yu, Ding, Yu, Shi-Ying, Hu, Yi, Chen, Ming, Chen, Gong-Yan, Fan, Yun, Zhang, He-Long, Liang, Jun, Zhu, Guang-Ying, Cui, Jiu-Wei, Yang, Jin-Ji, Zhao, Qiong, Zhao, Ming-Fang, Lu, You, Chang, Jian-Hua, Li, Jun-Ling, Yang, Yue, Hu, Jie, Gu, Chun-Dong, Zhang, Yi-Chen, Zhong, Wen-Zhao
Publicado no ESMO Open (2017)

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor...

Por Burris, Howard A, Bakewell, Suzanne, Bendell, Johanna C, Infante, Jeffrey, Jones, Suzanne F, Spigel, David R, Weiss, Glen J, Ramanathan, Ramesh K, Ogden, Angela, Von Hoff, Daniel
Publicado no ESMO Open (2017)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment

Por Martinelli, Erika, Sforza, Vincenzo, Cardone, Claudia, Capasso, Anna, Nappi, Anna, Martini, Giulia, Napolitano, Stefania, Rachiglio, Anna Maria, Normanno, Nicola, Cappabianca, Salvatore, Reginelli, Alfonso, Bisceglie, Maurizio Di, Latiano, Tiziana Pia, Maiello, Evaristo, Orditura, Michele, Vita, Fernando De, Morgillo, Floriana, Ciardiello, Fortunato, Troiani, Teresa
Publicado no ESMO Open (2017)

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe

Por Pavlidis, Nicholas, Alba, Emilio, Berardi, Rossana, Bergh, Jonas, El Saghir, Nagi, Jassem, Jacek, Kosty, Michael, Lopez, Roberto Ivan, Lotz, Jean-Pierre, Österlund, Pia, Purkalne, Gunta, Dittrich, Christian
Publicado no ESMO Open (2016)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer

Por Sartore-Bianchi, Andrea, Valtorta, Emanuele, Amatu, Alessio, Veronese, Silvio, Lauricella, Calogero, Bonazzina, Erica, Siravegna, Giulia, Truini, Mauro, Bardelli, Alberto, Siena, Salvatore
Publicado no ESMO Open (2016)